Navigation Links
Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
Date:12/11/2008

CARY, N.C., Dec. 11 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today provided an update on the status of its integration activities following the closing of the business combination of Critical Therapeutics, Inc. and Cornerstone BioPharma Holdings, Inc. on October 31, 2008, and the renaming of the combined company as Cornerstone Therapeutics Inc. (the Company).

Following the October 31, 2008 closing, the Company has been taking action to effectively and efficiently combine the operations of the two companies. In completing the integration, the Company has achieved a number of key milestones:

  • The Company has discontinued all former Critical Therapeutics research projects and completed a review of those research projects to identify promising technologies suitable for outlicensing to third parties. As a result of this review, the Company has initiated a process to seek potential licensees for certain technologies, including the alpha 7 mediated anti-inflammatory pathway program.
  • The Company completed a restructuring of former Critical Therapeutics officers and employees that resulted in Scott Townsend, General Counsel and Executive Vice President of Legal Affairs, and 12 former Critical Therapeutics sales representatives remaining with Cornerstone.
  • The former Critical Therapeutics facility in Lexington, MA has been vacated and the sublease terminated.

Aggregate revenues from the Company's products have continued to be strong in the fourth quarter. The Company anticipates 2008 net revenues to be in excess of $64 million, which will include revenues attributable to ZYFL
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015 PAREXEL International Corporation ... clinical research organization , announced today that ... to acquire all of the business assets of ... provider of specialized pharmacovigilance services, based in ... detection, assessment, monitoring, and prevention of adverse ...
(Date:3/26/2015)... America," the popular news television program that airs in numerous ... film actor James Earl Jones, has announced that it will ... , Botany is commonly described as the scientific study of ... more complicated than that. Scientists and other professionals study a ... smallest bacteria known to man to the largest trees that ...
(Date:3/26/2015)... WriteResult, a premier provider of ePRO technologies and ... of Public Health and New Haven Farms to capture ... project. The goal of the study was to evaluate ... access to fresh produce and nutrition education on food ... blood pressure, diabetes and weight gain. Patients completed an ...
(Date:3/25/2015)... 2015 Agnition announced today that it ... Farmer, airing for the first time at 7:30 a.m. ... Farmer will explore the extremely important role soil microbes ... a patented Microbial Catalyst™ technology that enhances soil and ... segment will air again on April 28. , A ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... SAN FRANCISCO, Calif., Dec. 8 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... and chief executive officer, will participate in a panel,discussion at ... Drugs and Targets for Inflammation and Rheumatology", will take,place on ... Westin Times,Square Hotel in New York City. , ...
... endpoint of non-inferiority to Pegasys (peginterferon alfa-2a) in the ACHIEVE ... hepatitis C - , , ... serious adverse events, severe adverse events and discontinuations due to ... , ROCKVILLE, Md., Dec. 8 Human Genome ...
... ATSI ), manufacturer and marketer of state-of-the-art cardiac surgery,products and ... of the ATS 3f(R) Aortic Bioprosthesis that includes a new ... , (Logo: ... the ATS 3f Aortic Bioprosthesis PMA was approved on October ...
Cached Biology Technology:Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 2ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis 3
(Date:3/12/2015)... VIEW, Calif. , March 12, 2015 /PRNewswire/ ... with Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: ... Manager Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... in order to compete in several different markets ... market is currently witnessing an uptrend. ...
(Date:3/10/2015)... -- Transforming How We Look at Medicine ... Human Space Flight" by Michael A. Schmidt ... was recently featured by Springer Science Media, highlighting the most ... Specifically, "Personalized Medicine in Human Space Flight" was among ... and 2014 from Springer in the journal Metabolomics ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... Researchers are delving into abnormal gene function in mitochondria, ... the place where energy is generated from the most ... to life, defects in mitochondria may affect a wide ... Some names of mitochondrial disorders are Leigh,s disease, ...
... research, published this week in Chemical Communications , ... insects, ability to detect plants by interfering with their ... by insect pests and contribute to food security. ... institute of BBSRC said: "One way in which insects ...
... that a University of Utah cardiologist proposes as a cause ... National Institutes of Health (NIH) likes to seeand reward with ... Pioneer Award. Ivor J. Benjamin, M.D., professor of internal ... of Cardiovascular Research at the U of U School of ...
Cached Biology News:How mitochondrial gene defects impair respiration, other major life functions 2How mitochondrial gene defects impair respiration, other major life functions 3Scientists discover how to send insects off the scent of crops 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 2Groundbreaking model of heart disease rewarded with NIH Pioneer Award 3
Anti 7H6 Antigen (tight-junction associated protein Antigen) Monoclonal Antibody 7H6...
... Rabbit Antibody to ARG. Vasopressin ... vasopression peptide. Cells are found in ... fibers are found throughout the hypothalmus ... perfused tissue. Immunogen: ...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Biology Products: